Foresight Diagnostics Reports Clinical Performance Data for ctDNA Assay in Early-Stage Lung Cancer
Study shows Foresight CLARITY demonstrated 68% pre-operative and 38% post-operative MRD detection rates in stage I lung cancer patients.
Read More
Search Results for: lung cancer
Mercy BioAnalytics Raises $59 Million Series B to Advance Cancer Detection Platform
The funding will support commercialization of the company’s extracellular vesicle-based liquid biopsy tests, starting with ovarian cancer screening.
Read More
New Multiomic Sequencing Platform Maps Genome and Epigenome in Single Assay
The new platform integrates genomic and epigenomic data in a single long-read sequencing assay, providing high-resolution insights into chromatin structure, gene regulation, and disease mechanisms.
Read More
Personalis MRD Test Shows Superior Sensitivity in Lung Cancer Trial
The test demonstrated higher baseline sensitivity for ctDNA detection compared to gene mutation-based testing in AstraZeneca’s NeoADAURA study.
Read More
Breath Analysis Technology Shows Promise for Pneumonia Prediction
Study demonstrates OneBreath platform can diagnose and predict pneumonia onset in cardiac surgery patients through volatile organic compound detection.
Read More